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Identity 
Other names: DP5; HARAKIRI; BID3 
HGNC (Hugo): HRK 
Location: 12q24.22 
Local order: According to Ensembl and the NCBI 
Map Viewer, the genes flanking HRK in the plus strand 
direction are: RNFT2, which is downstream of HRK 
and transcribed towards it, and FBXW8, which is 
upstream of HRK and transcribed divergently. 
Note: HRK / Dp5 / Bid3 is a BH3-only member of the 
Bcl-2 family of apoptosis regulators. Bcl-2 family 
proteins regulate the mitochondrial (intrinsic) pathway 
of apoptosis by regulating mitochondrial outer 
membrane permeability (Chipuk et al., 2010). 
Interactions between the pro- and anti-apoptotic 
members of the Bcl-2 family determine the fate of cells 
in response to signals that induce apoptosis. BH3-only 
proteins are activated in response to a variety of signals 
including survival factor withdrawal, DNA damage, ER 
stress and oxidative stress. HRK expression increases  
following Nerve Growth Factor (NGF) withdrawal in 
sympathetic neurons, neuronally differentiated PC12 
cells and dorsal root ganglion (DRG) neurons, KCl 
deprivation in cerebellar granule neurons, beta amyloid 
treatment in cortical neurons and following axotomy of 
motor neurons in vivo (Imaizumi et al., 1997; Imaizumi 
et al., 1999; Harris and Johnson, 2001; Imaizumi et al., 
2004; Coultas et al., 2007; Ma et al., 2007; Towers et 
al., 2009). Experiments with HRK-/- knockout mice 
have shown that HRK is not essential for normal 
embryonic development but does contribute to the 
death of DRG neurons following NGF deprivation in 
vitro (Coultas et al., 2007) and the death of 
motoneurons in vivo following hypoglossal nerve 
transection (Imaizumi et al., 2004). 
DNA/RNA 
Description 
The human HRK gene spans 20206 bases, telomere to 
centromere orientation. Exon 2, which encodes the 3 
UTR of the HRK mRNA, is much longer in the mouse ' 
 
Figure 1. Genomic context of the human HRK gene. HRK is located on chromosome 12 between the RNFT2 and FBXW8 genes. 
Arrows indicate the 5' to 3' orientation of each gene. Adapted from the NCBI Map Viewer. 
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Figure 2. HRK gene and promoter structure. A. Structure of the HRK gene. The structure of the human and rat HRK genes is shown. 
The HRK gene consists of two exons separated by a large intron. The transcriptional start site is indicated as +1 (see panel B for DNA 
sequence). Exon 1 contains the HRK open reading frame (black box) as well as a small region of the 3' UTR, the remainder of which is in 
exon 2. Exon 2 is longer in the rat and mouse genes compared to Exon 2 in human HRK. The human HRK transcript is 716 nucleotides 
long (Inohara et al., 1997) whereas the rat HRK transcript is 5253 nucleotides long due to the larger size of Exon 2 (Imaizumi et al., 
1997). B. HRK promoter sequence. Alignment of the promoter sequences for the rat, mouse, human and cow HRK genes. Shaded 
regions indicate a conserved ATF site, a GC box, an E box and a TATA box. * represent bases conserved in all four species. Overall, 
80% of the nucleotides are conserved. The transcriptional start site of the rat HRK gene determined by 5' RACE is indicated as +1, 
together with the direction of transcription (Towers et al., 2009). The HRK promoter has a similar structure in the four species except that 
there is a 10 bp deletion between the ATF site and putative GC box in the human gene, compared to the other species. Adapted from 
Figure 3 in Towers et al. (2009). 
 
and rat genes compared to human HRK (see Figure 
2A). In the three species only one major transcript 
encoding a single protein isoform has been described. 
Transcription 
In northern blotting experiments with RNA from 
human tissues, it was reported that the HRK transcript 
was detected in spleen, lymph nodes, thymus, bone 
marrow and appendix (Inohara et al., 1997). However, 
in the rat and mouse the expression of the HRK 
transcript is much more restricted and HRK is detect d 
in the brain but not the spleen, thymus, bone marrow, 
liver, lung, testis, heart, intestine or skeletal muscle 
(Imaizumi et al., 1997; Coultas et al., 2007). 
Based on studies with the rat HRK gene (Ma et al., 
2007; Towers et al., 2009), the 1 kb region upstream of 
exon 1 contains elements important for the control of 
HRK transcription (Figure 2B). The HRK promoter is 
GC-rich but contains a conserved block of 14 A/T 
nucleotides that might function as a TATA box, a 
conserved E-box, a conserved GC box and a conserved 
and functionally-important ATF binding site (5'-
TGATGTAA-3') that binds c-Jun and ATF2 and which 
is important for the  
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Figure 3. Structure of the human and rat HRK proteins. Amino acid residues in the 91 amino acid human HRK protein are numbered. 
Residues that are identical in the human and rat HRK proteins are shaded. Gaps are indicated by -. The BH3 domain and 
transmembrane domain are marked by black lines. 
 
activation of HRK transcription by the JNK pathway 
following survival factor withdrawal in neurons (Ma et 
al., 2007; Towers et al., 2009) or exposure to pro-
inflammatory cytokines in pancreatic beta-cells 
(Gurzov et al., 2009). 
Pseudogene 
There are no known pseudogenes for HRK. 
Protein 
Description 
Only one isoform of the HRK protein has been 
described. HRK is 91 amino acids long in humans and 
92 amino acids in mouse and rat (Inohara et al., 1997; 
Imaizumi et al., 1997; Imaizumi et al., 1999). 
Expression 
See section on transcription for information about 
tissue specificity. The endogenous HRK protein has 
been detected in immunoblotting experiments with a 
number of cell types, for example: in NGF-deprived rat 
primary sympathetic neurons in culture (Imaizumi et 
al., 1997), in the mouse brain following focal cerebral 
ischemia (middle cerebral artery occlusion; Gao et al., 
2005), in the auditory cell line HEI-OC1 exposed to 
gentimicin (Kalinec et al., 2005) and in the pancreatic 
beta-cell line INS-1E treated with the pro-inflammatory 
cytokines IL-1beta and IFNgamma (Gurzov et al., 
2009). 
Localisation 
HRK is a non-nuclear intracellular protein (Inohara et 
al., 1997). Flag-tagged HRK co-localizes with 
MitoTracker in transfected COS-7 cells suggesting that
HRK predominantly localizes to mitochondria 
(Sunayama et al., 2004). Studies with a 27 amino acid 
peptide containing the putative transmembrane domain 
of HRK indicated that this domain is able  
to insert into membranes, where it adopts a 
transmembrane alpha-helical structure (Bernabeu et al., 
2007). This suggests that the carboxy terminal region 
of HRK may insert into the mitochondrial outer 
membrane. 
Function 
HRK is a pro-apoptotic BH3-only member of the Bcl-2 
protein family. Overexpression of HRK can induce 
apoptosis in HEK293 cells (Inohara et al., 1997; 
Imaizumi et al., 1999), rat sympathetic neurons 
(Imaizumi et al., 1997) and cerebellar granule neurons 
(Harris and Johnson, 2001). In these cell types 
HRK/DP5-induced apoptosis is blocked by co-
expression of Bcl-2 or Bcl-xL (Inohara et al., 1997; 
Imaizumi et al., 1997) or by knockout of the 
endogenous Bax gene (Harris and Johnson, 2001). The 
HRK protein contains two functional domains: a BH3 
domain and a carboxy terminal transmembrane domain 
(Figure 3). The HRK BH3 domain is related in amino 
acid sequence to the BH3 domains of other Bcl-2 
family proteins and is required for interaction with anti-
apoptotic Bcl-2 family proteins, such as Bcl-2 and Bcl-
xL, and for cell death induced by overexpression of 
HRK (Inohara et al., 1997). A detailed study of the 
binding of BH3-only proteins to anti-apoptotic Bcl-2 
family members indicated that HRK binds with high 
affinity to Bcl-xL, Bcl-w and A1 and with moderate 
affinity to Bcl-2 and Mcl-1 (Chen et al., 2005). The 
HRK transmembrane domain is rich in hydrophobic 
amino acid residues and could mediate the insertion of 
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the HRK carboxy terminus into intracellular 
membranes, such as the mitrochondrial outer 
membrane. 
Homology 
The HRK protein is only related to other Bcl-2 family 
proteins in the short BH3 domain. 
Mutations 
Note 
No mutations have been described in HRK. 
Implicated in 
Colorectal and gastric cancer 
Note 
The region around the HRK transcriptional start site 
was methylated in 36% of colorectal and 32% of 
gastric cancer cell lines and was closely associated with 
a loss of HRK expression in those cell lines (Obata et 
al., 2003; Nakamura et al., 2009). HRK expression was
restored by treatment with a methyltransferase 
inhibitor, 5-aza-deoxycytidine, and further enhanced by 
addition of the histone deacetylase inhibitor trichostatin 
A or depsipeptide. The restoration of HRK expression 
correlated with an induction of apoptosis and 
enhancement of Adriamycin-induced apoptosis. 
Expression of other proapoptotic genes, including 
BAX, BAD, BID, and PUMA, was unaffected by 
treatment with 5-aza-deoxycytidine. Aberrant 
methylation of HRK was also frequently detected in 
primary colorectal cancers that showed methylation of 
multiple genes. 
Disease 
Colorectal cancer (bowel cancer) is characterized by 
neoplasia in the colon, rectum or vermiform appendix. 
Colorectal cancers start in the lining of the bowel. If 
left untreated, they can grow into the muscle layers 
underneath, and then through the bowel wall. Most 
begin as a small growth on the bowel wall - a colorectal 
polyp or adenoma. These growths are usually benign, 
but some develop into cancer over time. Colorectal 
cancer is the third most commonly diagnosed cancer i  
the world. 
Gastric cancer (stomach cancer) can develop in any 
part of the stomach and may spread throughout the 
stomach and to other organs, in particular the 
oesophagus, lungs, lymph nodes and the liver. Stomach 
cancer causes about 800000 deaths worldwide per year. 
Glioblastoma 
Note 
The region around the HRK transcriptional start site 
was methylated in 19% of diffuse astrocytomas, in 22% 
of anaplastic astrocytomas, in 27% of primary 
glioblastomas, and in 43% of secondary glioblastomas 
(Nakamaura et al., 2005; Nakamura et al., 2009). HRK 
expression was significantly reduced in 61% of 
secondary glioblastomas as compared to other types of 
tumours, and aberrant methylation was closely 
associated with loss of expression. Reverse 
transcription-PCR analysis also demonstrated a clear 
agreement between reduced HRK protein levels and 
low or absent HRK transcripts. 
Disease 
Glioblastoma (WHO grade IV) is the most frequent and
most malignant tumour of the human nervous system. 
Despite advances in surgery and adjuvant therapy, 
glioblastoma patients still have a very poor prognosis. 
From a clinical and biological point of view, 
glioblastomas are divided into two subtypes. Primary or 
de novo glioblastomas develop rapidly, without clini al 
or histopathological evidence of less malignant 
precursor lesions and constitute the majority of 
diagnosed cases, whereas secondary glioblastoma 
develops more slowly and progressively from low-
grade diffuse (WHO grade II) or anaplastic (WHO 
grade III) astrocytoma. 
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